Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced that its CARE Program (Comprehensive, Assessment, Risk, and ...
The government has invested £4.75 million in a genomic sequencing programme aimed at identifying the biological causes of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), in what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results